Methotrexate Single-dose Treatment and Methotrexate/Actinomycin-D Single-dose Treatment in Low-Risk Gestational Trophoblastic Neoplasia (GTN-01)
A Multicenter, Prospective, Randomized Trial of Methotrexate Single-dose Treatment and Methotrexate/Actinomycin-D Single-dose Treatment in Low-Risk Gestational Trophoblastic Neoplasia
Sponsor: Ding Ma
Listed as NCT01823315, this PHASE3 trial focuses on Gestational Trophoblastic Disease and Gestational Trophoblastic Neoplasia and remains ongoing. Sponsored by Ding Ma, it has been updated 8 times since 2012, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Jan 2022 — Jul 2024 [monthly]
Unknown Status PHASE3
Status: Active Not Recruiting → Unknown Status
-
Jan 2021 — Jan 2022 [monthly]
Active Not Recruiting PHASE3
-
Jan 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
▶ Show 3 earlier versions
-
Feb 2019 — Jan 2020 [monthly]
Active Not Recruiting PHASE3
-
Jun 2018 — Feb 2019 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
First recorded
Dec 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ding Ma
- Huazhong University of Science and Technology
- Shandong University
- Zhejiang University
For direct contact, visit the study record on ClinicalTrials.gov .